Extracellular ATP signaling in equine digital blood vessels.
The functional distribution of ATP-activated P2 receptors is well characterized for many blood vessels, but not in the equine digital vasculature, which is a superficial vascular bed that displays thermoregulatory functions and has been implicated in ischemia-reperfusion injuries of the hoof. Isolated equine digital arteries (EDA) and veins (EDV) were submitted to isometric tension studies, whereby electric field stimulation (EFS) and concentration-response curves to exogenously applied agonists were constructed under low tone conditions. Additionally, immunofluorescent localization of P2X and P2Y receptor subtypes was performed. EFS-induced constriction was abolished by tetrodotoxin (1 μM, n=4). Endothelium denudation did not modify the EFS-induced constriction (n=3). The EFS-induced constriction in EDA was inhibited by phentolamine (67.7±1.8%, n=6; 10 μM), and by the non-selective P2 receptor antagonist suramin (46.2±1.3%, n=6; 10 μM). EFS-induced constriction in EDV was reduced by suramin (48.2±2.4%, n=6; 10 μM), the P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (58.3±4.5%, n=6; 10 μM), and phentolamine (23.2±2.5%, n=6; 10 μM). Exogenous methoxamine and ATP mimicked EFS-induced constriction in EDA and EDV. Immunostaining for P2X1, P2X2 and P2X3, and, for P2X1 and P2X7 receptor subunits were observed in EDA and EDV smooth muscle and adventitia, respectively. ATP and noradrenaline are co-transmitters in sympathetic nerves supplying the equine digital vasculature, noradrenaline being the dominant agonist in EDA, and ATP in EDV. In conclusion, P2X receptors mediate vasoconstriction in EDA and EDV, although different P2X subunits are involved in these vessels. The physiological significance of this finding in relation to thermoregulatory functions and equine laminitis is discussed.
Biomedical Department, Faculty of Veterinary Sciences, Central University of Venezuela, Maracay, Bolivarian Republic of Venezuela. hectorzerpa@gmail.com
Hector
H
Zerpa
Carol
C
Crawford
Gillian E
GE
Knight
Alice F
AF
Fordham
Silvia E
SE
Janska
Claire M
CM
Peppiatt-Wildman
Jonathan
J
Elliott
Geoffrey
G
Burnstock
Scott S
SS
Wildman
D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology*; D000818:Animals; D001158:Arteries / Q000187:drug effects* / Q000502:physiology; D004558:Electric Stimulation; D005260:Female; D006736:Horses; D066298:In Vitro Techniques; D008297:Male; D008729:Methoxamine / Q000494:pharmacology; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D018048:Receptors, Purinergic P2 / Q000502:physiology; D058469:Receptors, Purinergic P2X / Q000502:physiology*; D013498:Suramin / Q000494:pharmacology; D014544:Uridine Triphosphate / Q000494:pharmacology; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014680:Veins / Q000187:drug effects* / Q000502:physiology
D018048:Receptors, Purinergic P2; D058469:Receptors, Purinergic P2X; D014662:Vasoconstrictor Agents; C077792:pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid; D011732:Pyridoxal Phosphate; D013498:Suramin; D000255:Adenosine Triphosphate; D008729:Methoxamine; C002630:alpha,beta-methyleneadenosine 5'-triphosphate; D014544:Uridine Triphosphate